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Abstract
Animal sport doping control laboratories are constantly reviewing ways in which they
can improve their service offering whilst ensuring that they remain economically via-
ble. This paper describes the development and assessment of a rapid and economical
method for the detection of intact glucuronide conjugates of three anabolic steroids
and their metabolites along with three corticosteroids in canine urine. The analysis of
intact drug conjugates for animal sport doping control is generally not performed rou-
tinely as it presents a number of analytical challenges, not least of which is the lack of
availability of appropriate reference standards. Here, we report the development of a
UHPLC–MS/MS method using APCI in the negative ion mode for the detection of
intact phase II conjugates, including the importance of in vitro incubations in order to
provide appropriate reference materials. Cross-validation of the developed method
demonstrated that the detection capability of the intact phase II conjugates of
stanozolol, boldenone, nandrolone, and their metabolites along with the corticoste-
roids dexamethasone and methylprednisolone was equivalent to that achieved in
routine race-day screens. The new process has been in operation for approximately
2 years and has been used to analyze in excess of 13500 canine urine samples,
resulting in a number of positive screening findings. To the best of our knowledge,
this is the first reported use of a routine screen for intact drug conjugates within ani-
mal sport doping control.
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1 | INTRODUCTION
In 2011, the Greyhound Board of Great Britain (GBGB) instigated the
Point of Registration (POR) testing program.1 At that time there was a
perception within the sport that some animals were being adminis-
tered long acting prohibited substances, such as anabolic steroids, in
order to gain a performance improvement whilst in training. Many of
these animals would then be sold on to new owners prior to com-
mencing a racing career. With the sale price being dependent upon
their performance whilst in training, it is clear to see how improved
performance could result in an increased sale price.
The POR test was introduced in order to provide a layer of pro-
tection against this practice, to increase buyer confidence when pur-
chasing racing greyhounds, and to demonstrate an on-going
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commitment to the integrity of the sport. From May 2011 onwards,
all animals that were taken to a racecourse for microchipping and reg-
istration to race were required to have a urine sample collected at the
same time.1 This urine sample was collected in a tamper evident sam-
ple kit, given a unique and anonymized sample identifier and subse-
quently transported to the laboratory at LGC for long-term frozen
storage.
If a racing greyhound was subsequently tested positive for a
prohibited substance in the first 6 months from the time of its regis-
tration then the POR sample would be removed from long-term stor-
age and analyzed in order to determine if the substance was present
at the time of registration. The results from both tests would then be
available to the GBGB for consideration at any subsequent enquiry.
This approach allowed the GBGB to collect samples from all regis-
tered animals but was also relatively low cost with just a small storage
fee being applicable to all samples and an analysis fee only for those
samples that required testing.
In 2016, the GBGB proposed a change in the way in which the
samples collected as part of the POR program were processed. The
new approach would see all samples analyzed within 10 working days
of their receipt in the laboratory for a selection of prohibited sub-
stances known to be of long duration. As this test was to be applied
to all animals newly registered with the GBGB, there was a require-
ment to make the analytical procedure as cost effective as possible
and therefore the number of analytes covered was restricted to a
number of key compounds of interest. The analytes selected for inclu-
sion in the first iteration of the method were the anabolic steroids
boldenone, nandrolone, and stanozolol along with the corticosteroids
dexamethasone, betamethasone, and methylprednisolone. This group
of analytes was based upon the results obtained from the routine
screening of race-day urine samples performed at LGC and following
consultation with the GBGB.
The aim of the new method was to provide equivalent coverage,
in terms of detection capability, to that achieved in the routine
screens in place at LGC for anabolic steroids and corticosteroids in
race-day greyhound urine. As such there was no requirement to quan-
titatively validate the method but rather to assess its performance
against the current screening protocols, which we termed cross-
validation throughout the work. An adverse screening finding from
the POR test results in the dog being prevented from racing until such
time as a negative result is obtained.
Urine has always been the matrix of choice for greyhound doping
control as it is easy to collect and generally contains higher analyte
concentrations than blood. As such, the methods employed by animal
sport doping control laboratories are based upon the detection of
drugs in urine and in many cases this requires the extraction and anal-
ysis of phase I and phase II metabolites. In the dog, conjugation with
glucuronic acid is the most important phase II metabolic reaction of
anabolic steroids.2-4 Therefore, the analysis of anabolic steroids in
greyhound urine is usually undertaken following enzymatic hydrolysis
using β-glucuronidase enzymes to cleave the glucuronic acid and to
release the phase I metabolites. The main benefit to this approach is
that liberated phase I metabolites are usually suitable for chemical
derivatization and subsequent analysis by gas chromatography mass
spectrometry (GC–MS), which has traditionally been the analytical
technique of choice for the detection of anabolic steroids and their
metabolites in animal sport doping control.2-5 In addition, phase I
metabolites are usually more readily available as reference standards,
which greatly assists with method development.
Whilst relatively sparse, there are previous reports on the detec-
tion of intact phase II conjugates of anabolic steroids from animal
sport doping control laboratories. As early as 1983, Dumasia et al.
reported on the successful detection of intact sulfate conjugated
boldenone in equine urine6 using fast-atom bombardment MS, but
the method was hampered by high levels of matrix interference and
was not suitable for routine testing. In 2002, the detection of endoge-
nous intact boldenone sulfate in the urine of colts was reported by
the group of Ho et al.7 This work subsequently led to the establish-
ment of an internationally agreed threshold for the detection of
boldenone in the urine of intact male horses. Grace et al.8 reported a
method for the detection of intact sulfate conjugates of both
boldenone and nandrolone in the urine of male horses. The authors
overcame an issue of interference from high concentrations of sulfate
conjugates of the female sex hormones estrone and estradiol by selec-
tive hydrolysis of aryl sulfates using glucuronidase from Helix pomatia.
This approach allowed for the targeted hydrolysis of the aryl sulfates
of estrone and estradiol without any significant hydrolysis of the alkyl
sulfates of nandrolone and boldenone. By following up this highly
targeted hydrolysis approach with a targeted solid phase extraction,
the newly liberated “free” phenolic steroids were removed to waste
and the retained nandrolone and boldenone sulfates subsequently
eluted.
The analysis of intact conjugated anabolic steroids has a number
of potential advantages, not least of which is the elimination of the
enzyme hydrolysis step, which is both timely and costly due to the
requirement for high quality purified enzyme solution. There are also
concerns that variation in the hydrolysis step from one batch to
another may lead to unreliable and unreproducible results.9,10 In addi-
tion, when employing liquid chromatography tandem mass spectrome-
try, the intact conjugates ionize readily in both the positive and
negative mode without the need for a time consuming derivatization
step. As such, the analysis of intact phase II conjugates has been
investigated in human urine samples, primarily for doping control pur-
poses.11-17 This approach has gained acceptance and is used to com-
plement the more traditional approach to steroid analysis in urine
samples. Whilst the detection of intact drug conjugates, particularly of
anabolic steroids, is reported for human sport doping control, there is
very little information available on its routine use in animal sport dop-
ing control.
Whilst offering undoubted benefits, the successful development
of methods for the detection of intact phase II conjugates is compli-
cated by the lack of availability of appropriate reference standards.
For those compounds for which reference materials are not commer-
cially available the synthesis of phase II steroid conjugates by in vitro
incubation offers a means by which methods can be developed and
assessed.18,19 This approach is seen as vital to the continued
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development of methods for the routine analysis of intact drug conju-
gates and has the significant benefit of reducing, and in many cases
eliminating, the requirement for expensive and ethically contentious
animal administration studies.
Unlike anabolic steroids, corticosteroids are largely excreted as
either phase I metabolites or as unchanged drug in canine urine20,21
and their analysis is usually performed by LC–MS/MS. In our labora-
tory race-day screening of canine urine is performed by high-
resolution mass spectrometry hyphenated to ultra-high performance
liquid chromatography (UHPLC-HRMS).
Despite the reporting of a number of successful demonstrations
of the detection of intact steroid conjugates in equine urine,6-8 to date
and to the best of our knowledge there are no reported screening
methods that specifically target intact conjugates for routine animal
sport doping control purposes. In addition, there are no reported
methods for the detection of intact anabolic steroid conjugates in
canine urine. To address the problem of including both glucuronic acid
conjugated anabolic steroids and non-conjugated corticosteroids in a
single analysis, a simple and rapid method was developed and cross-
validated.
2 | EXPERIMENTAL
2.1 | Reagents and standards
Betamethasone, dexamethasone, methylprednisolone, and boldenone
were obtained from Sigma-Aldrich (Gillingham, UK), stanozolol was
from Toronto Research Chemicals (Toronto, Canada), and boldenone
glucuronide, 19-noreticholanolone glucuronide, 19-norandrosterone
glucuronide, and d4-androsterone glucuronide were from the
Australian Government National Measurement Institute (Sydney,
Australia). Stock solutions containing individual compounds at concen-
trations of 1 mg/mL were prepared in methanol and stored at −20C.
Infusion solutions of individual analytes at a concentration of 1 μg/mL
were prepared in methanol. A mixed stock solution containing all of
the compounds, except for the deuterated internal standard, was pre-
pared at a concentration of 10 μg/mL in methanol and was subse-
quently used to prepare spiking solutions at appropriate
concentrations. The deuterated internal standard (d4-androsterone
glucuronide) was prepared in methanol at a concentration of 10 μg/mL
and subsequently diluted to prepare appropriate spiking solutions.
Method development was performed using canine urine which had
previously been screened and shown to be free of any of the analytes
of interest. Development and cross-validation of the method also
required the use of canine urine samples previously shown to contain
one or more of the analytes of interest. These samples were retrieved
from long term frozen storage at LGC Fordham.
All analytical grade chemicals were from either Fisher Scientific
(Loughborough, UK) or Sigma-Aldrich (Gillingham, UK). Bond Elute
Nexus solid phase extraction cartridges (3 mL, 60 mg) were from
Agilent Technologies (Wokingham, UK). Reagent grade water was
purified using a Triple Red Duo water system (Triple Red Laboratory
Technologies, Long Crendon, UK). in vitro incubations were per-
formed using canine liver S9 fraction (Xenotech, Kansas City, USA),
trizma HCl, trizma base, UDPGA, and NADH (Sigma-Aldrich, Gilling-
ham, UK) and NADPH (Park Scientific, Northampton, UK).
2.2 | UHPLC–MS/MS
In order to minimize both method development time and the require-
ment to switch analytical columns and mobile phases, the UHPLC–
MS/MS method was based upon an amended version of that already
in use in our laboratory for the routine screening of corticosteroids in
equine urine. The corticosteroid method utilizes atmospheric pressure
chemical ionization (APCI) in the negative ion mode to detect intact
acetate adducts of a wide range of corticosteroids and associated
compounds [Unpublished].
The mass spectrometer was a 5500 triple quadrupole from Sciex
(Framingham, USA). For those analytes for which suitable reference
standards were available (boldenone glucuronide,
19-noreticholanalone glucuronide and 19-norandrosterone glucuro-
nide, d4-androsterone glucuronide, betamethasone, dexamethasone,
and methylprednisolone) SRM transitions (three or four per analyte)
and source conditions were established by direct infusion of 1 μg/mL
solutions into the APCI source of the mass spectrometer. Optimiza-
tion of SRM transitions for the remaining analytes, for which refer-
ence standards were not available, was performed by the repeat loop-
injection of extracts derived from in vitro incubations of parent drug.
As it was not possible to obtain a reference standard for
19-norepiandrosterone glucuronide (expected canine metabolite of
nandrolone) its epimer, 19-norandrosterone glucuronide, which was
available, was used to establish SRM and source conditions. Whilst it
was anticipated that the fragmentation of the two analytes would be
very similar and hence the SRM transitions would be appropriate, it
was possible that the retention time of the two analytes would differ
and hence the retention time of 19-norepiandrosterone was
established by the analysis of urine samples previously shown to be
positive for nandrolone metabolites.
Following establishment of mass spectrometry conditions, chro-
matographic separation was performed using an Acquity Classic UPLC
system with an Acquity BEH C18 (100 × 2.1, 1.7 μm) column (Waters,
Milford, USA). Chromatographic conditions were optimized to ensure
appropriate separation between the analytes of interest and other
matrix components, whilst ensuring that the analysis could be com-
pleted in as short a time frame as possible.
Mobile phase A was acetonitrile and mobile phase B was
20 mM pH 6.8 acetate buffer in reagent grade water. Initial condi-
tions were 10% A, which was held for 30 seconds before following a
linear gradient up to 50% A at 3.5 minutes and a further climb to
100% A at 4.0 minutes. This was held until 4.8 minutes before
returning to the initial starting conditions at 5.0 minutes followed by
a 1 minute re-equilibration period, giving a total run time of
6 minutes. The column temperature was held at 60C and the injec-
tion volume was 10 μL.
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2.3 | In vitro incubations
As glucuronide conjugated reference materials were not commer-
cially available for many of the expected metabolites of boldenone
and stanozolol there was a requirement to undertake in vitro
incubations in order to provide extracts containing the conjugated
steroid metabolites. Reference standards of both stanozolol and
boldenone were incubated with canine liver S9 fraction and
appropriate buffers and co-factors in order to form phase II
metabolites.
4 μL of the 1 mg/mL drug standards (in methanol) were added
to sample tubes containing 190 μL of 50 mM Tris buffer, 83 μL of
2.5 mM NADPH cofactor solution and 50 μL of S9 cofactor solu-
tion before the addition of 16.7 μL of canine liver S9 microsomes.
The samples were vortexed briefly and incubated at 37C for
180 minutes at which point the reaction was quenched and an ali-
quot removed and centrifuged at 11000 rpm for 10 minutes. Fol-
lowing in vitro incubation the extracts were evaporated to dryness,
re-dissolved in 50:50 acetonitrile: 20 mM pH 6.8 phosphate buffer
(v:v) and analyzed in the full-scan mode in order to identify the
expected [M-H]− precursor ions. Product ion scans of the precur-
sor ions were then used in order to identify potential SRM transi-
tions. Repeat injections allowed optimization of the source and
collision cell conditions.
2.4 | Sample extraction
In order to minimize the sample preparation time and the associ-
ated cost, the extraction method was based upon that already in
use within our laboratory for the extraction of a wide range of
acidic and neutral drugs in canine urine [unpublished]. Briefly, 2 mL
of canine urine was diluted with 2 mL of 1 M pH 6.3 phosphate
buffer containing d4-androsterone glucuronide as an internal
marker. The sample was centrifuged for 15 minutes at 3000 rpm
before being applied to a Bond Elute Nexus SPE cartridge (3 mL,
60 mg) pre-conditioned with 1 mL of methanol and 1 mL of water.
After washing with 0.5 mL of hexane and drying with nitrogen, the
free fraction, containing the unconjugated corticosteroids, was
eluted with 1 mL of ethyl acetate, which was retained. The car-
tridge was then dried with nitrogen and the conjugated steroids
eluted with 1 mL of methanol into a fresh tube. An optimized vol-
ume (100 μL) of the ethyl acetate eluent, containing the corticoste-
roids, was transferred to the methanol eluent and mixed well
before the combined eluent was evaporated to dryness. The dried
extract was reconstituted in 1 mL of 10% methanol in water ready
for analysis.
2.5 | Method cross-validation
As a rapid and cost-effective screen there was no requirement for full
method validation. The aim of the POR screen was to produce
detection capability for the selected analytes equivalent to that
obtained by the routine canine race-day screens in place within our
laboratory. Detection of any presumptive screening positives via the
POR screen would result in the queried sample being re-extracted
using the appropriate race-day canine urine screen, all of which are
fully validated and ISO17025 accredited. Hence, method performance
was primarily confirmed by direct comparison with these race-day
screening methods.
Method performance was initially assessed by spiking blank
greyhound urine (dog and bitch) with those analytes for which refer-
ence standards were available, at concentrations of 0, 0.5, 1, 5,
10, and 20 ng/mL (as intact glucuronide conjugates for anabolic ste-
roid metabolites and as free drug for corticosteroids – bet-
amethasone and dexamethasone spiked individually as they were
observed to co-elute). These concentrations were selected based
upon the validated performance of the race-day screening methods
against which the POR method was to be cross-validated
[unpublished]. Spiked samples were extracted and analyzed using
both the POR screen and the routine race-day canine urine screens.
The detection capability (estimated limit of detection) of both
approaches was determined by comparison of the results. Further
evaluation of the POR screen for those analytes that were not avail-
able as reference standards was performed by the extraction and
analysis of canine urine samples which had previously been tested
positive for the drugs of interest or, where available, the analysis of
urine samples collected following the administration of stanozolol,
boldenone, and nandrolone.
Method selectivity and system robustness was assessed by the
extraction and analysis of a batch of 30 POR urine samples. The data
were reviewed for interfering peaks and the response of the deuter-
ated internal marker.
2.6 | Addition of norethisterone metabolites
After analyzing genuine POR samples for a period of approximately
10 months, it became clear that there were a significant number of
adverse screening findings for nandrolone metabolites in bitch urine.
In 2011, the GBGB permitted the use of norethisterone as an
estrus suppressant in racing greyhounds.22 Investigation of its
administration to greyhounds has previously been shown to lead to
the detection of the nandrolone metabolites 19-noreticholanalone
and 19-norepiandrosterone in female greyhounds, due to the pres-
ence of nandrolone and 19-norandrostenedione as low level contami-
nants within the norethisterone tablets.23
In order to successfully clear these animals as fit to race, it was
necessary to re-extract the urine samples and analyze them using
GC–MS for the presence of both nandrolone and norethisterone
metabolites. However, re-extracting and analyzing samples using a dif-
ferent technique added an additional layer of complexity and cost to
the screening process and therefore the decision was made to investi-
gate the addition of suitable norethisterone markers to the POR
screen.
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3 | RESULTS AND DISCUSSION
3.1 | UHPLC–MS/MS optimization
Screening of corticosteroids in equine urine is currently performed at
our laboratory using APCI in the negative ion mode. It was expected
that the intact glucuronide conjugates of boldenone, nandrolone, and
stanozolol would also ionize well in this mode and hence method
development focused on the APCI source and negative ionization.
For those analytes for which reference standards were available,
SRM transitions and source conditions were optimized by direct infu-
sion of 1 μg/mL solutions of the individual standards. For those
analytes for which reference standards were not available, repeat
loop-injections of in vitro incubates allowed the establishment of
SRM transitions.
The selection of appropriate analytes for inclusion in the method
was based upon a number of factors, primarily the experience avail-
able within the laboratory, gained from many years of analyzing race-
day canine urine samples [unpublished], along with reference to publi-
shed work on the metabolism of anabolic steroids in the canine.4,23-27
As per the work presented by Mckinney et al.4 three compounds were
included for the detection of boldenone. Boldenone glucuronide itself,
an A-ring reduced metabolite (boldenone metabolite 1 glucuronide),
and an A-ring reduced metabolite with further reduction of the
3-ketone (boldenone metabolite 2 glucuronide). For the detection of
nandrolone, two glucuronide conjugated metabolites were selected
for inclusion in the method, being 19-norepiandrosterone glucuronide
and 19-noreticholanolone glucuronide.23,25,26 Detection of stanozolol
was achieved via the monitoring of three analytes, glucuronidated
stanozolol itself and mono- and di-hydroxylated stanozolol
conjugates.24,27
All analytes were shown to ionize well in the negative ion APCI
mode, with the deprotonated ion, [M-H]−, being the most abundant
species for the glucuronide conjugated anabolic steroids. This is con-
sistent with previous studies on the detection of intact steroid conju-
gates.11-16 The free corticosteroids produce strong acetate adducts,
[M + acetate]−, in the negative ion mode, again consistent with previ-
ous work20,21,28 and the current race-day screen for corticosteroids in
equine urine used within our laboratory. A minimum of three SRM
transitions were established for each analyte, with the strongest one
or two being used as primary screening transitions during post run
data processing. The final optimized SRM transitions are shown in
Table 1.
The UHPLC conditions established were based upon those
already in use for the analysis of corticosteroids in equine urine,
amended to improve the chromatographic separation of early eluting
compounds from matrix interferants. Initial investigations of the
corticosteroid screening method revealed that the earlier eluting
glucuronide conjugated anabolic steroids were badly affected by
interference from matrix peaks. As a result, the mobile phase gradient
was adjusted and the method lengthened by a total of 1.5 minutes.
This minor alteration to the LC conditions resulted in much
improved chromatography for the conjugated anabolic steroids and
TABLE 1 SRM transitions (negative ion APCI) included in the POR
method (s- indicates screening transition(s) included in
post-acquisition processing method)
Analyte
SRM
RT (min)Q1 Q3
Androsterone glucuronide d4 (IM) 469 113 s 2.90
290 s
19-Norepiandrosterone glucuronide
and19-noretiocholanolone
glucuronide
451 113 s 2.55/2.73
157 s
273
95
Boldenone glucuronide 461 113 2.34
285
283 s
Boldenone metabolite 1 glucuronide
463
463 287 2.80
75
85 s
113
Boldenone metabolite 2 glucuronide
465
465 289 3.35
75
85
113
175 s
Dexamethasone/betamethasone 451 361 s 3.41
307
325
Methylprednisolone 433 294 3.35
309 s
343
Stanozolol glucuronide 503 327 s 2.48
85
75
113
Stanozolol OH glucuronide 519 343 s 2.02
327
85
75
Stanozolol di-OH glucuronide 535 359 s 1.78
85 s
75
113
Norethisterone glucuronide 473 339 2.34
323 s
Norethisterone diol metabolite
glucuronide
343 s 2.61
477 327
315
Norethisterone triol metabolite
glucuronide
493 493 1.91/2.07
113
85
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consequently improved detection capability with only a small
increase in total run time.
Post-acquisition data processing was performed using Analyst
software (Sciex, Framingham, USA) to produce a single page report
displaying one or two SRM transitions for each analyte. This report
format allows for very rapid data checking, which is vital in a high
throughput screening environment. An example data report (compos-
ite) showing the main screening transitions for each analyte is shown
in Figure 1 (excluding recently added norethisterone metabolites). If a
potential screening positive is identified following review of the report
then the remaining SRM transitions can be interrogated to provide
additional confidence in the finding. At this stage, any potential
screening positives are re-extracted using the appropriate race-day
screen for canine urine, all of which are fully validated and ISO17025
accredited.
3.2 | In vitro incubations
In vitro incubations were performed in order to provide material con-
taining phase II metabolites of both stanozolol and boldenone. Analy-
sis of the full scan data from the in vitro incubates revealed the
presence of a number of expected glucuronide conjugates and three
phase II metabolites were selected for both boldenone and stanozolol
(Table 1). Successful formation and detection of the expected phase II
metabolites in the full scan mode was followed by repeat injections in
the product ion scan mode at various collision energies. In this way a
minimum of three SRM transitions were selected for each analyte and
source and collision cell conditions optimized.
The use of in vitro incubations in order to provide sufficient mate-
rial for method development and optimization was vital to the success
of this work due to the commercial unavailability of many of the
F IGURE 1 Composite screening data report compiled from spiked urine samples and in-vitro incubates (arrows indicate peaks of interest)
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expected phase II metabolites. The use of in vitro technologies in
order to produce appropriate reference materials for use in animal
sports is described in the 2106 ILAC-G7 document (2016 Interna-
tional Laboratory Cooperation – G7: Accreditation requirements and
operating criteria for horseracing laboratories).29 These guidelines
state that in vitro generated reference materials are appropriate for
the confirmation of the presence of a prohibited substance where
in vivo administration samples are not available (article 16.4).
Whilst it is possible to perform similar development and optimiza-
tion using extracts from post-administration samples, these are often
not available for the drugs of interest, are in short supply or have con-
centrations of metabolites too low to be of practical use. Using
in vitro incubations also has the significant benefit of reducing and in
some cases eliminating the requirement for expensive and ethically
contentious animal administration studies. The importance of in vitro
studies in the development of methods for the detection of prohibited
substances in animal sports has been demonstrated previously, with
research primarily concentrating on equine sport and therefore equine
metabolism. In 2010, Scarth et al. reported on the application of
in vitro technologies in order to study the metabolism of stanozolol in
the equine.18 This was followed up by a paper detailing the study of a
new designer steroid, estra-4,9-diene-3,17-dione. Using in vitro incu-
bation allowed for the comparison of metabolite profiles in human,
canine, and equine models,30 without the need for expensive adminis-
tration studies, which would have been ethically questionable given
the undefined toxicological profile of the drug being studied. The
application of in vitro technology to the study of new and emerging
drugs, particularly designer steroids, was fully discussed by Clarke
et al.31 who investigated eight designer steroids available via the
internet.
3.3 | Sample extraction
Sample extraction was based upon that already in use for the extrac-
tion of acidic and neutral drugs in canine urine with a number of
important modifications. Initially the free corticosteroid fraction was
eluted in ethyl acetate and retained, the cartridge was then dried and
the conjugated steroids eluted with methanol. The two extracts were
then combined so that a single injection could be made. The initial
ethyl acetate eluent contained a large amount of matrix material and
therefore a decision was made to minimize the volume of this eluent
that needed to be added back to the methanol extract.
As the purpose of the POR screen was to achieve equivalent
detection capability to that of the routine canine urine screens, it was
necessary to optimize the volume of ethyl acetate added back to the
methanol elution until the same or similar detection capability was
reached. Optimization of this step was carried out using canine urine
samples spiked with the three corticosteroids at 1 ng/mL and
extracted using both the POR method and the relevant race-day
screening method. Different volumes (50, 100, 200, 500, and
1000 μL) of the free corticosteroid fraction were added back into the
conjugated fraction and the results compared with the results
obtained from the race-day screen.
Comparison of differing volumes of the ethyl acetate eluent dem-
onstrated that transfer of just 100 μL of the free fraction resulted in a
similar method performance to that obtained following extraction of
the same spiked sample using the race-day screen for corticosteroids.
A comparison of the addition of 50, 100, and 200 μL of the free frac-
tion eluent is shown in Figure 2. The optimization of this step was
critical in ensuring the required detection capability for both the con-
jugated anabolic steroids and the un-conjugated corticosteroids from
F IGURE 2 Comparison of peak response for three SRM transitions for dexamethasone following addition of 50, 100 and 200 μL of the ethyl
acetate eluent (free fraction) back into the methanol eluent (conjugated fraction)
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a single extract. Addition of higher volumes of the ethyl acetate elu-
tion resulted in improved detection of the corticosteroids but the
additional matrix loading had a negative impact on the detection of
the conjugated steroids.
Combining two extracts from a single SPE protocol, one con-
taining the free corticosteroids and the other containing the conju-
gated anabolic steroids and their metabolites was vital to maintain
the cost effectiveness of the method. The extraction of drugs from
liquid samples is a major part of the work of a doping control labora-
tory and forms a significant portion of the overall cost of sample
analysis, as it is generally a manual process that is both time-
consuming and requires the use of single-use SPE cartridges. Mini-
mizing both the man hours and consumables required was therefore
critical in order to produce a method that achieved the required
detection capability whilst ensuring that costs were kept at a level
which was acceptable to the both the client and the laboratory. We
believe that this is the first time such an approach has been pres-
ented for the routine screening of corticosteroids and anabolic ste-
roids in canine urine.
3.4 | Method cross-validation
Whilst full validation was not required, the performance of the POR
method was assessed to ensure that it met the original aim of the pro-
ject, which was equivalent detection capability to that of the race-day
screens. For those compounds for which reference standards were
available the method was assessed by the analysis of canine urine
samples (bitch and dog) spiked at 0, 0.5 1, 2, 5, 10, and 20 ng/mL. The
results of this analysis are shown in Table 2.
For those compounds available as reference standards the POR
screen was demonstrated to have equivalent, and in some cases
slightly improved, detection capabilities to that of the current race-
day screening methods. For the corticosteroids detection was possible
using the POR screen at 0.5 ng/mL for betamethasone, dexametha-
sone, and methylprednisolone. The equivalent race-day screening
method (general screen for acidic and neutral drugs by LC-HRMS)
provides detection at 1–5 ng/mL for betamethasone and dexametha-
sone and 5–10 ng/mL for methylprednisolone [unpublished]. There is
no recent published information on the detection of corticosteroids in
canine urine and therefore it is not possible to assess critically the
detection capability of the developed POR method against previously
published methods. However, assessment against the race-day
screens already in place within our laboratory shows that the analyti-
cal approach of the POR screen is at least as sensitive and could, if
required, provide sensitivity in excess of that obtained for routine
race-day screening. This additional sensitivity was achieved as a result
of the more targeted approach of the POR screen, which utilizes
selected reaction monitoring on a high sensitivity triple quadrupole
mass spectrometer rather than the non-targeted approach of the
race-day screen, using the broad range screening capability of a high
resolution mass spectrometer. The additional sensitivity available from
the POR screen allowed for optimization of the volume of the free
steroid fraction added back into the methanol eluent containing the
conjugated steroids. In this way the sensitivity of the method for cor-
ticosteroids was able to be aligned with that of the race-day screen
and had the added benefit of minimizing the amount of co-extracted
matrix material that the mass spectrometer was exposed to.
For boldenone glucuronide the detection capability was similar in
both the POR and the appropriate race-day screening method
TABLE 2 Method comparison of those analytes available as reference standards and spiked into canine urine
Screen
Dexamethasone/betamethasone Methylprednisolone
19-Noreticholanolone and
19-norepiandronsterone glucuronide
Boldenone
glucuronide
POR Race-day POR Race-day POR Race-day POR Race-day
Dog blank O O O O O O O O
Dog 0.5 ng/mL ✓ O ✓ O O O O O
Dog 1 ng/mL ✓ O ✓ O ✓* ✓* O O
Dog 5 ng/mL ✓ ✓ ✓ O ✓ ✓ ✓ ✓*
Dog 10 ng/mL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Dog 20 ng/mL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Bitch blank O O O O O n/a O O
Bitch 0.5 ng/mL ✓ O ✓ O O n/a O O
Bitch 1 ng/mL ✓ ✓* ✓ O ✓* n/a O O
Bitch 5 ng/mL ✓ ✓ ✓ O ✓ ✓ ✓ ✓*
Bitch 10 ng/mL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Bitch 20 ng/mL ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓, peak detected;
O, not detected
✓
*, peak detected but S/N less than 10
n/a, interference from norethisterone in bitch urine.
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(anabolic steroids by GC–MS following enzyme hydrolysis), with
detection possible at 5 ng/mL in both dog and bitch urine. This
detection capability is broadly in line with that recently reported for
intact glucuronide conjugates of boldenone and its metabolites
in human urine.32 Detection of the nandrolone metabolites
19-norepiandrosterone and 19-noreticholanolone was possible in dog
urine at 1 ng/mL in both methods. The analysis of spiked bitch urine
was complicated by the presence of norethisterone metabolites in the
spiked urine, but detection of the nandrolone metabolites was possi-
ble at between 1 and 5 ng/mL using both methods. As the same bitch
urine was used for both the POR and the race-day anabolic steroid
screen, it was considered that analytical performance was comparable
across both methods.
Analysis of spiked urine samples containing the intact glucuronide
metabolites of the anabolic steroids for which reference materials
were available produced results that were similar across the current
race-day screens and the POR screen. These results were also largely
in line with the reported detection capability for intact conjugates of
anabolic steroids in human urine,32 which was the only comparison
possible due to the absence of any corresponding information from
canine urine.
The analysis of selected past-positive and post-administration
canine urine samples allowed a comparison of method performance
for those anabolic steroid metabolites for which glucuronide conju-
gated reference standards were not available. It also allowed a test of
the method for selected other analytes, such as dexamethasone, in
genuine samples rather than via spiked samples. The results of these
comparisons are shown in Table 3.
For the two dexamethasone past-positives analyzed, dexametha-
sone was successfully detected using the POR screen but was not
observed in the corresponding extract analyzed using the race-day
screen. As was demonstrated with spiked urine samples (Table 2) the
POR screen offers a slightly improved detection capability for the
selected corticosteroids over and above the current race-day screen-
ing protocol. As such the difference in detection capability was not
unexpected and is in line with the results obtained from spiked sam-
ples. The past-positive dexamethasone samples analyzed had been
held in cold storage (nominally −20C) for approximately 5 years and
therefore it is considered likely that the samples had degraded over
that time, which resulted in their failure to be detected using the cur-
rent race-day screen.
Stanozolol detection was compared by the analysis of two past-
positive urine samples and a single post-administration urine sample.
In each case the detection capability was similar across the POR
screen and the relevant race-day screening protocol, in this case a LC-
HRMS screen for basic drugs in canine urine. The post-administration
(PA) sample was strongly positive in both screens, producing good
chromatographic peaks in the POR screen for stanozolol glucuronide
and both mono- and di-hydroxy glucuronide metabolites. Extracted
ion chromatograms for the screening transitions for stanozolol glucu-
ronide, hydroxy-stanozolol glucuronide and di-hydroxy stanozolol glu-
curonide from the PA sample and a blank canine urine are shown in
Figure 3. This shows one distinct peak for stanozolol glucuronide, two
peaks for mono-hydroxylated stanozolol glucuronide, and four peaks
for di-hydroxylated metabolites. Without suitable reference standards
it is not possible to positively identify the stereochemistry of the
detected metabolites, but the presence of multiple mono- and di-
hydroxylated metabolites is entirely consistent with previous work on
the excretion of stanozolol in canine and equine urine.18,24,27
The equivalent sample analysed using the basic drug screen for
canine urine produced good chromatographic peaks for mono- and di-
hydroxy stanozolol metabolites by LC-HRMS following enzyme
hydrolysis. The two past-positive samples analyzed had both been
stored at −20C for a number of years and were both low in volume,
potentially compromising the analysis. Detection of stanozolol metab-
olites was possible in both samples using the POR screen, with mono-
TABLE 3 Method comparison of those analytes present in past-positive or post-administration (PA) samples
Method
Dexamethasone Stanozolol and metabolites Nandrolone metabolites Boldenone and metabolites
POR Race-day POR Race-day POR Race-day POR Race-day
Dexamethasone
Past-positive
✓ O
Dexamethasone
Past-positive
✓ O
Stanozolol past-positive ✓* ✓*
Stanozolol past-positive ✓* ✓*
Stanozolol PA ✓ ✓
Nandrolone past-positive ✓ ✓
Nandrolone past-positive ✓ ✓
Boldenone past-positive ✓ ✓
Boldenone PA ✓ ✓
✓, peak detected
O, not detected
✓
*, peak detected but S/N less than 10.
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and di-hydroxy glucuronide metabolites being observed, albeit at con-
siderably lower peak responses than observed in the post-
administration sample. This was repeated in the extracts obtained
from the race-day screening protocol, in which small peaks were
observed for mono- and di-hydroxy metabolites. The results from the
analysis of stanozolol past-positives and a stanozolol post-
administration sample show that the detection capability of the POR
screen for stanozolol is comparable to that of the current race-day
screening method.
Comparison of the detection capability for boldenone and its
metabolites was compromised by the lack of appropriate past-positive
and post-administration samples. A single example of each was avail-
able and the post-administration sample was very low in volume. As
such, a lower volume of the past-positive was extracted, therefore
reducing method capability. The past-positive urine sample was also
known to be at a very low concentration and hence its detection was
expected to be challenging. In both cases it was possible to detect
boldenone and/or metabolites using the POR screen and the ‘anabolic
steroids by GC-MS’ race-day screen. The post-administration sample
gave the best peak responses on both screens and showed that detec-
tion capability across the screens was comparable (the screening tran-
sitions for all three boldenone phase II metabolites from this sample
are included in the composite data processing report – Figure 1).
Detection was also possible for the past-positive sample although
detection was challenging, with small peaks being observed in the
POR screen for the intact glucuronide metabolites and the GC–MS
screen for the equivalent enzyme hydrolyzed metabolites.
Two canine urine samples which were previously shown to be
positive for nandrolone metabolites were analyzed using the POR
screen and the ‘anabolic steroids by GC-MS’ race-day screen. In each
case the appropriate metabolites were observed in both the POR and
race-day screens. As seen in the spiked urine samples, detection
capability for nandrolone metabolites is comparable across the two
methods.
Method robustness and selectivity was assessed by the analysis
of 30 genuine POR urine samples. SRM transitions were interrogated
for the presence of interfering matrix peaks and the peak response of
the deuterated internal marker was monitored. In all samples the
internal marker, d4-androsterone glucuronide, was detected with a
signal to noise ratio of significantly greater than 10. Matrix peaks were
observed in some of the transitions selected for the anabolic steroid
conjugates but these were at different retention times to the actual
peaks and could be eliminated by comparison of the relative retention
time (RRT against d4-androsterone glucuronide). Subsequent analysis
of over 13500 genuine POR samples has shown that matrix peaks are
occasionally detected in the screening transitions of all of the anabolic
steroid conjugates. In most cases these can be eliminated by the use
of RRT and interrogation of the additional SRM transitions. Where
this is not possible the sample is re-extracted using the appropriate
race-day screen as an orthogonal extraction and detection technique.
This allows for the confident identification of genuine screening
findings.
3.5 | Addition of norethisterone metabolites to
assist data checking
Once established and in routine use the analysis of genuine POR sam-
ples demonstrated that there were a number of adverse screening
findings for nandrolone metabolites that were occurring in bitch urine.
Previous work by Biddle et al.23 had shown that nandrolone metabo-
lites could be present in bitch urine as a result of the administration of
norethisterone, which is given in order to control the estrus cycle.
These metabolites arise as a result of the presence of low level
F IGURE 3 Extracted ion
chromatograms of stanozolol
glucuronide (bottom), OH-
stanozolol glucuronide (middle)
and di-OH stanozolol glucuronide
(top) in a POR sample returning
an adverse analytical finding for
stanozolol (left hand traces) and a
blank sample from the same
batch (right hand traces)
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contamination of the norethisterone tablets with nandrolone and
19-norandrostenedione. It was therefore surmised that these nandro-
lone finding were in fact as a result of the administration of
norethisterone and not as a result of the purposeful administration of
nandrolone. As such the decision was taken to add norethisterone
markers to the POR screen in order to assist with interpretation of
the analytical data.
As per the work described by Biddle et al.23 several
norethisterone metabolites are detected in canine urine following
administration, with the major metabolites being various diols, triols,
and tetrols. These metabolites are excreted primarily as intact glucu-
ronide conjugates and hence should be suitable for inclusion within
the POR method. Unfortunately, none of these compounds were
available to the laboratory as intact glucuronide conjugated reference
standards and therefore method development was based upon the
extraction and repeat analysis of greyhound urine samples previously
shown to contain high concentrations of norethisterone metabolites.
This allowed the identification and optimization of SRM transitions
for intact glucuronide conjugates of these analytes without the need
for reference standards. The analytes selected for inclusion in the
method were norethisterone glucuronide along with transitions for di-
and tri-hydroxylated glucuronide metabolites (Table 1).
The addition of norethisterone metabolites to the POR screen
greatly assisted with data interpretation, allowing for the majority of
bitch samples that show evidence of nandrolone metabolites to be
cleared to race without the requirement for costly additional testing.
4 | CONCLUSIONS
An UHPLC–MS/MS method for the analysis of intact glucuronide
conjugates of selected anabolic steroids and their metabolites along
with three corticosteroids was developed and introduced as a routine
screening protocol. The method covers metabolites of the anabolic
steroids, nandrolone, boldenone, and stanozolol, along with the corti-
costeroids betamethasone, dexamethasone, and methylprednisolone.
After a 10 month monitoring period the decision was made to also
add appropriate metabolites of the estrus suppressant norethisterone
in order to assist with data interpretation. The use of in vitro incuba-
tions to produce intact phase II conjugates was critical to the success-
ful development of the method, as suitable reference standards were
not available for the majority of the expected metabolites.
The method was designed to offer a rapid and economical solu-
tion to the screening of POR urine samples collected by the GBGB. In
order to keep sample processing time and method costs to a minimum
the decision was taken to analyze intact glucuronide conjugates and
also to utilize existing UHPLC–MS/MS instrumentation and condi-
tions. By analyzing intact glucuronide conjugates in negative ion APCI
it was also possible to analyze non-conjugated corticosteroids as their
acetate adducts at the same time. This approach allows for rapid
transfer between screening methods and improved utilization of labo-
ratory instrumentation, a vital consideration for a busy commercial
laboratory.
The method has now been in operation for approximately 2 years
and has been used to successfully analyze over 13500 POR samples.
In that time period a number of adverse screening findings (approxi-
mately 0.4%) have been identified, primarily nandrolone metabolites,
but also metabolites of stanozolol, boldenone, and both dexametha-
sone and methylprednisolone. These results have led to the dogs in
question being prohibited from racing until such time as they return a
negative result. We believe that this is the first reported routine anal-
ysis of intact glucuronide conjugates in an animal sport doping control
laboratory and the first time that this approach has been investigated
in canine urine.
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